933 related articles for article (PubMed ID: 18657708)
21. Life expectancy of people with HIV on antiretroviral therapy in Spain.
Jarrín I; Rava M; Del Romero Raposo J; Rivero A; Del Romero Guerrero J; De Lagarde M; Martínez Sanz J; Navarro G; Dalmau D; Blanco JR; Koerting A; Gomez Castell J; Del Amo J;
AIDS; 2024 Mar; 38(3):387-395. PubMed ID: 37905999
[TBL] [Abstract][Full Text] [Related]
22. Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy.
Losina E; Schackman BR; Sadownik SN; Gebo KA; Walensky RP; Chiosi JJ; Weinstein MC; Hicks PL; Aaronson WH; Moore RD; Paltiel AD; Freedberg KA
Clin Infect Dis; 2009 Nov; 49(10):1570-8. PubMed ID: 19845472
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies.
Trickey A; McGinnis K; Gill MJ; Abgrall S; Berenguer J; Wyen C; Hessamfar M; Reiss P; Kusejko K; Silverberg MJ; Imaz A; Teira R; d'Arminio Monforte A; Zangerle R; Guest JL; Papastamopoulos V; Crane H; Sterling TR; Grabar S; Ingle SM; Sterne JAC
Lancet HIV; 2024 Mar; 11(3):e176-e185. PubMed ID: 38280393
[TBL] [Abstract][Full Text] [Related]
24. Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies.
Kaulich-Bartz J; Dam W; May MT; Lederberger B; Widmer U; Phillips AN; Grabar S; Mocroft A; Vilaro J; van Sighem A; Moreno S; Dabis F; Monforte AD; Teira R; Ingle SM; Sterne JA;
AIDS; 2013 Jun; 27(10):1641-55. PubMed ID: 23449349
[TBL] [Abstract][Full Text] [Related]
25. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
[TBL] [Abstract][Full Text] [Related]
26. Sustained 10-year gain in adult life expectancy following antiretroviral therapy roll-out in rural Malawi: July 2005 to June 2014.
Price AJ; Glynn J; Chihana M; Kayuni N; Floyd S; Slaymaker E; Reniers G; Zaba B; McLean E; Kalobekamo F; Koole O; Nyirenda M; Crampin AC
Int J Epidemiol; 2017 Apr; 46(2):479-491. PubMed ID: 28338707
[TBL] [Abstract][Full Text] [Related]
27. Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model.
Braithwaite RS; Roberts MS; Chang CC; Goetz MB; Gibert CL; Rodriguez-Barradas MC; Shechter S; Schaefer A; Nucifora K; Koppenhaver R; Justice AC
Ann Intern Med; 2008 Feb; 148(3):178-85. PubMed ID: 18252681
[TBL] [Abstract][Full Text] [Related]
28. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.
Palella FJ; Baker RK; Moorman AC; Chmiel JS; Wood KC; Brooks JT; Holmberg SD;
J Acquir Immune Defic Syndr; 2006 Sep; 43(1):27-34. PubMed ID: 16878047
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 disease progression and mortality before the introduction of highly active antiretroviral therapy in rural Uganda.
Van der Paal L; Shafer LA; Todd J; Mayanja BN; Whitworth JA; Grosskurth H
AIDS; 2007 Nov; 21 Suppl 6():S21-9. PubMed ID: 18032935
[TBL] [Abstract][Full Text] [Related]
30. Life expectancy trends in adults on antiretroviral treatment in South Africa.
Johnson LF; Keiser O; Fox MP; Tanser F; Cornell M; Hoffmann CJ; Prozesky H; Boulle A; Davies MA;
AIDS; 2016 Oct; 30(16):2545-2550. PubMed ID: 27428744
[TBL] [Abstract][Full Text] [Related]
31. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients.
Antiretroviral Therapy Cohort Collaboration
J Acquir Immune Defic Syndr; 2007 Dec; 46(5):607-15. PubMed ID: 18043315
[TBL] [Abstract][Full Text] [Related]
32. Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study.
Migrants Working Group on behalf of COHERE in EuroCoord
Lancet HIV; 2015 Dec; 2(12):e540-9. PubMed ID: 26614968
[TBL] [Abstract][Full Text] [Related]
33. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
Egger M; May M; Chêne G; Phillips AN; Ledergerber B; Dabis F; Costagliola D; D'Arminio Monforte A; de Wolf F; Reiss P; Lundgren JD; Justice AC; Staszewski S; Leport C; Hogg RS; Sabin CA; Gill MJ; Salzberger B; Sterne JA;
Lancet; 2002 Jul; 360(9327):119-29. PubMed ID: 12126821
[TBL] [Abstract][Full Text] [Related]
34. Life expectancy in the immune recovery era: the evolving scenario of the HIV epidemic in northern Italy.
Guaraldi G; Cossarizza A; Franceschi C; Roverato A; Vaccher E; Tambussi G; Garlassi E; Menozzi M; Mussini C; Dʼarminio Monforte A
J Acquir Immune Defic Syndr; 2014 Feb; 65(2):175-81. PubMed ID: 24442223
[TBL] [Abstract][Full Text] [Related]
35. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.
Palella FJ; Deloria-Knoll M; Chmiel JS; Moorman AC; Wood KC; Greenberg AE; Holmberg SD;
Ann Intern Med; 2003 Apr; 138(8):620-6. PubMed ID: 12693883
[TBL] [Abstract][Full Text] [Related]
36. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
[TBL] [Abstract][Full Text] [Related]
37. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
[TBL] [Abstract][Full Text] [Related]
38. Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda.
Mills EJ; Bakanda C; Birungi J; Chan K; Hogg RS; Ford N; Nachega JB; Cooper CL
J Int AIDS Soc; 2011 Nov; 14():52. PubMed ID: 22050673
[TBL] [Abstract][Full Text] [Related]
39. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia.
Lloyd-Smith E; Brodkin E; Wood E; Kerr T; Tyndall MW; Montaner JS; Hogg RS
AIDS; 2006 Feb; 20(3):445-50. PubMed ID: 16439879
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.
Amogne W; Aderaye G; Habtewold A; Yimer G; Makonnen E; Worku A; Sonnerborg A; Aklillu E; Lindquist L
PLoS One; 2015; 10(5):e0122587. PubMed ID: 25966339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
